InvestorsHub Logo
Followers 139
Posts 23730
Boards Moderated 0
Alias Born 04/08/2004

Re: biodoc post# 79904

Saturday, 11/29/2014 1:05:48 AM

Saturday, November 29, 2014 1:05:48 AM

Post# of 403524
Biodoc:

Entremed had licensed their rights to thalidomide from Boston's Children's Hospital for Dr. D'Amato's patent

Filed 1995

The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5593990.PN.&OS=PN/5593990&RS=PN/5593990

Also, Dr. Moses Judah Folkman's patent for anti-angiogenesis filed in 1988

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4994443.PN.&OS=PN/4994443&RS=PN/4994443

By the way Celgene's Revlimid was a derivative of Thalidomide covered transferred to Celgene from Entremed.

Good luck and GOD bless,

George
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News